Oppenheimer & Co. Inc. boosted its position in shares of Zoetis Inc. (NYSE:ZTS) by 40.0% during the second quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 112,016 shares of the company’s stock after buying an additional 32,014 shares during the period. Oppenheimer & Co. Inc.’s holdings in Zoetis were worth $6,988,000 as of its most recent SEC filing.

Several other hedge funds have also recently bought and sold shares of ZTS. BlackRock Inc. raised its stake in Zoetis by 2,471.1% in the first quarter. BlackRock Inc. now owns 36,082,470 shares of the company’s stock worth $1,925,722,000 after buying an additional 34,679,064 shares in the last quarter. Vanguard Group Inc. raised its stake in Zoetis by 1.7% in the first quarter. Vanguard Group Inc. now owns 32,744,421 shares of the company’s stock worth $1,747,570,000 after buying an additional 546,287 shares in the last quarter. State Street Corp raised its stake in Zoetis by 4.9% in the first quarter. State Street Corp now owns 21,256,557 shares of the company’s stock worth $1,134,453,000 after buying an additional 986,680 shares in the last quarter. Morgan Stanley raised its stake in Zoetis by 182.5% in the first quarter. Morgan Stanley now owns 14,617,205 shares of the company’s stock worth $780,119,000 after buying an additional 9,442,207 shares in the last quarter. Finally, Clearbridge Investments LLC raised its stake in Zoetis by 4.2% in the first quarter. Clearbridge Investments LLC now owns 9,254,662 shares of the company’s stock worth $493,921,000 after buying an additional 373,568 shares in the last quarter. Institutional investors own 93.31% of the company’s stock.

Shares of Zoetis Inc. (NYSE:ZTS) opened at 62.65 on Friday. Zoetis Inc. has a 1-year low of $46.86 and a 1-year high of $63.85. The firm’s 50-day moving average is $61.77 and its 200 day moving average is $58.63. The company has a market cap of $30.64 billion, a price-to-earnings ratio of 35.42 and a beta of 1.02.

Zoetis (NYSE:ZTS) last posted its quarterly earnings data on Tuesday, August 8th. The company reported $0.53 earnings per share for the quarter, meeting the consensus estimate of $0.53. Zoetis had a return on equity of 62.49% and a net margin of 17.50%. The company had revenue of $1.27 billion during the quarter, compared to analysts’ expectations of $1.27 billion. During the same period in the prior year, the business earned $0.49 earnings per share. Zoetis’s revenue for the quarter was up 5.0% compared to the same quarter last year. Equities analysts expect that Zoetis Inc. will post $2.34 EPS for the current fiscal year.

WARNING: “Oppenheimer & Co. Inc. Has $6.99 Million Position in Zoetis Inc. (ZTS)” was first posted by Watch List News and is owned by of Watch List News. If you are accessing this piece on another domain, it was illegally stolen and reposted in violation of US & international copyright and trademark laws. The legal version of this piece can be read at https://www.watchlistnews.com/oppenheimer-co-inc-has-6-99-million-position-in-zoetis-inc-zts/1536060.html.

ZTS has been the topic of a number of analyst reports. Jefferies Group LLC lifted their price objective on shares of Zoetis from $65.00 to $70.00 and gave the company a “buy” rating in a research note on Tuesday, May 9th. Cantor Fitzgerald set a $75.00 price objective on shares of Zoetis and gave the company a “buy” rating in a research note on Monday, August 14th. Stifel Nicolaus reiterated a “buy” rating and set a $65.00 price objective on shares of Zoetis in a research note on Friday. Argus reiterated a “buy” rating and set a $69.00 price objective (up previously from $60.00) on shares of Zoetis in a research note on Tuesday, May 30th. Finally, CL King initiated coverage on shares of Zoetis in a research note on Friday, May 26th. They set a “buy” rating and a $71.00 price objective on the stock. One equities research analyst has rated the stock with a sell rating, five have given a hold rating and twelve have issued a buy rating to the company’s stock. The company has a consensus rating of “Buy” and a consensus price target of $65.44.

About Zoetis

Zoetis Inc is engaged in the discovery, development, manufacture and commercialization of animal health medicines and vaccines, with a focus on both livestock and companion animals. The Company has a business, commercializing products across eight core species: cattle, swine, poultry, sheep and fish (collectively, livestock) and dogs, cats and horses (collectively, companion animals), and within five product categories: anti-infectives, vaccines, parasiticides, medicated feed additives and other pharmaceuticals.

Want to see what other hedge funds are holding ZTS? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Zoetis Inc. (NYSE:ZTS).

Institutional Ownership by Quarter for Zoetis (NYSE:ZTS)

Receive News & Ratings for Zoetis Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Zoetis Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.